株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗体医薬品:技術および世界市場

Antibody Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 230632
出版日 ページ情報 英文 115 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.40円で換算しております。
Back to Top
抗体医薬品:技術および世界市場 Antibody Drugs: Technologies and Global Markets
出版日: 2017年10月01日 ページ情報: 英文 115 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の抗体医薬品市場は、2016年には808億米ドルの規模に達しました。さらに、2017年には845億米ドル、2022年には1146億米ドルと、6.3%のCAGR (複合年間成長率) で成長する見通しです。

当レポートでは、抗体医薬品の世界市場に注目し、モノクローナル抗体 (mAb) 医薬品の市場構造・用途や関連規制、市場規模の推移と見通し (過去3年間・今後6年間分)、ゲノミクス市場・バイオテクノロジー市場全体に対する将来的な影響、主要企業のプロファイル、主要製品の治験の進行状況といった情報を取りまとめてお届けいたします。

第1章 イントロダクション

第2章 サマリー・ハイライト

第3章 市場・技術の背景事情

  • 抗体と抗原
  • 抗体の機能
  • モノクローナル抗体
    • モノクローナル抗体の歴史
    • モノクローナル抗体の利点と欠点
    • モノクローナル抗体の種類
    • モノクローナル抗体の製造技術
    • モノクローナル抗体の活用分野

第4章 技術の種類別の市場区分

  • 種類別の市場
    • 市場概要
    • 市場収益額
    • 市場シェア
  • 地域別の市場
    • 市場概要
    • 市場収益額
    • 市場シェア
    • マウスモノクローナル抗体
    • キメラ化モノクローナル抗体
    • ヒトモノクローナル抗体
    • ヒト化モノクローナル抗体
  • 製造過程別の市場
    • 市場概要
    • 市場収益額
    • 市場シェア
    • マウスモノクローナル抗体の市場分析:製造工程別
    • キメラ化モノクローナル抗体の市場分析:製造工程別
    • ヒトモノクローナル抗体の市場分析:製造工程別
    • ヒト化モノクローナル抗体の市場分析:製造工程別

第5章 用途別の市場区分

  • 疾患別の市場
    • 市場概要
    • 市場収益額
    • 市場シェア
    • 自己免疫疾患
    • 固形腫瘍
    • 悪性リンパ腫・白血病
    • その他

第6章 産業構造

  • マウスモノクローナル抗体
    • 市場リーダー
    • 市場シェア
  • キメラ化モノクローナル抗体
  • ヒト化モノクローナル抗体
  • ヒトモノクローナル抗体

第7章 規制関連の動向

  • モノクローナル抗体の新規認証
  • リコール
  • 安全警告

第8章 特許分析/新規開発

  • 特許分析
    • 特許申請件数:年度別
    • 特許申請件数:種類別
    • 特許申請件数:企業別
    • 特許申請件数:国別
    • 特許申請件数:譲受人別
  • 新規開発
    • 第?相治験
    • 第?相治験
    • 第?相治験
    • 第?相治験
  • 企業合併・買収 (M&A)

第9章 市場機会の分析

  • 技術的課題
  • HAMA (ヒト抗マウス抗体) 問題
  • モノクローナル抗体 (mAb) 医薬品市場への影響要因
    • 慢性疾患の有病者数の増加
    • 人口高齢化
    • 薬価規制
    • 規制上の認証
    • 医薬品メーカー間の競争激化
    • 製造技術の進歩
    • バイオシミラー
    • 企業合併・買収 (M&A)
    • ライセンス契約

第10章 企業プロファイル

付録:略語一覧

BCC Researchについて

付録:図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: BIO016K

The global market for antibody drugs reached $80.8 billion in 2016. The market should reach $114.6 billion by 2022 increasing from $84.5 billion in 2017, at a compound annual growth rate (CAGR) of 6.3% from 2017 through 2022.

Report Includes

  • An overview of the global market for therapeutic monoclonal antibody (mAb) drugs and related applications and technologies.
  • Analyses of global market trends, with data from 2014, 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Analysis and assessment of the therapeutic applications of mAbs in human medicine.
  • A look at the antibody industry as a whole, as well as a discussion of the pending huge impact of genomics and the emergence of biotechnology firms into the mainstream market.
  • Comprehensive profiles of companies that lead the biotechnology and pharmaceutical industries in the research and development of antibody drugs and the innovative products that those companies have launched or have in development.

Report Scope

This study offers a global view of the antibody drugs used in the pharmaceutical and biopharmaceutical markets. This report analyzes and assesses therapeutic applications of monoclonal antibodies (mAbs) in human medicine, including the combination of mAbs when they are attached to cytotoxic agents such as antibody drug conjugates.

BCC Research analyzes and makes projections for each market and its applications, the regulatory environment, new products and technological advances. Also included in the report are relevant patent analysis and profiles of leading companies in the antibody drug industry, such as AbbVie Inc., Amgen Inc., Biogen Inc., Johnson & Johnson Inc., Merck KGaA, Novartis AG, F. Hoffmann-La Roche Ltd. and Merck & Co.

The report covers the major markets of the U.S. and Europe, as well as emerging markets in India, China, Japan, Korea, Taiwan, Africa, Australia, New Zealand, Canada, etc.

Monoclonal antibodies are protein-based therapies/drugs that are finding use in the treatment of number of chronic diseases. This report focuses on the global market for antibody drug products and provides an updated review on their applications in various disease sectors. The overall market for antibody drug products includes four main areas of applications: autoimmune diseases; solid tumors; lymphoma and leukemia; and other diseases such as asthma, osteoporosis and cardiovascular diseases.

The report covers technology trends, including the human anti-mouse antibody (HAMA) problem caused by murine antibodies and how it was resolved by replacing murine antibodies with chimeric, human and humanized antibodies.

Excluded from this report are polyclonal antibodies; screening kits; and diagnostic uses of mAbs. Also excluded are research applications of mAbs and therapeutic antibodies for veterinary use.

Analyst Credentials

SHALINI DEWAN focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master\'s degree in medicinal chemistry. She resides in the Bay Area.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Antibodies and Antigens
  • Antibody Functions
  • Monoclonal Antibodies
    • History of Monoclonal Antibodies
    • Advantages and Disadvantages of Monoclonal Antibodies
    • Types of Monoclonal Antibodies
    • Manufacturing Technologies of Monoclonal Antibodies
    • Applications of Monoclonal Antibodies

Chapter 4: Market Breakdown by Technology Type

  • Market by Type
    • Market Overview
    • Market Revenue
    • Market Share
  • Market by Region
    • Market Overview
    • Market Revenue
    • Market Share
    • Murine Monoclonal Antibodies
    • Chimeric Monoclonal Antibodies
    • Human Monoclonal Antibodies
    • Humanized Monoclonal Antibodies
  • Market by Manufacturing Process
    • Market Overview
    • Market Revenue
    • Market Share
    • Market of Murine Monoclonal Antibodies by Manufacturing Process
    • Market Analysis of Chimeric Monoclonal Antibodies by Manufacturing Process
    • Market Analysis of Human Monoclonal Antibodies by Manufacturing Process
    • Market Analysis of Humanized Monoclonal Antibodies by Manufacturing Process

Chapter 5: Market Breakdown by Application

  • Market by Diseases
    • Market Overview
    • Market Revenue
    • Market Share
    • Autoimmune Disease
    • Solid Tumors
    • Lymphoma and Leukemia
    • Others

Chapter 6: Industry Structure

  • Murine Monoclonal Antibodies
    • Market Leaders
    • Market Share
  • Chimeric Monoclonal Antibodies
    • Market Leaders
    • Market Share
  • Humanized Monoclonal Antibodies
    • Market Leaders
    • Market Share
  • Human Monoclonal Antibodies
    • Market Leaders
    • Market Share

Chapter 7: Regulatory Aspects

  • New Approvals of Monoclonal Antibodies
  • Recalls
  • Safety Alerts

Chapter 8: Patent Review/ New Developments

  • Patent Review
    • Patents by Year
    • Patents by Type
    • Patents by Company.
    • Patents by Country
    • Patents by Assignee
  • New Developments
    • Phase I clinical trials
    • Phase II clinical trials
    • Phase III Clinical Trials
    • Phase IV Clinical Trials
  • Mergers and Acquisitions

Chapter 9: Analysis of Market Opportunities

  • Technical Issues
  • Human anti-mouse antibody (HAMA) Problem
  • Factors Affecting mAb Drugs
    • Increasing Prevalence of Chronic Diseases
    • Aging Population
    • Price Regulation
    • Regulatory Approvals
    • Increasing Competition between Drug Makers
    • Advances in Manufacturing Technologies
    • Biosimilars
    • Mergers and Acquisitions
    • Licensing Agreements

Chapter 10: Company Profiles

Appendix: Abbreviations

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table Global Market for Antibody Drugs, by Disease, Through 2022 ($ Millions)
  • Table 1 Evolution of Monoclonal Antibodies
  • Table 2 Advantages and Disadvantages of Monoclonal Antibodies
  • Table 3 Murine Monoclonal Antibodies
  • Table 4 Chimeric Monoclonal Antibodies
  • Table 5 Humanized Monoclonal Antibodies
  • Table 6 Human Monoclonal Antibodies
  • Table 7 Differences between Hybridoma and Recombinant Technologies
  • Table 8 Murine Monoclonal Antibodies and Their Applications
  • Table 9 Chimeric Monoclonal Antibodies and Their Applications
  • Table 10 Human Monoclonal Antibodies and Their Applications.
  • Table 11 Humanized Monoclonal Antibodies and Their Applications
  • Table 12 Global Sales of Antibody Drugs, by Type, Through 2022 ($ Millions)
  • Table 13 Market Shares for Antibody Drugs, by Type, 2016 (%)
  • Table 14 Global Sales of Antibody Drugs, by Region, Through 2022 ($ Millions)
  • Table 15 Market Shares for Antibody Drugs, by Region, 2016 (%)
  • Table 16 Global Market for Murine Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 17 Global Market for Chimeric Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 18 Global Market for Human Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 19 Global Market for Humanized Monoclonal Antibodies, by Region, Through 2022 ($ Millions)
  • Table 20 Global Market for Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 21 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)
  • Table 22 Global Market for Murine Antibody Drugs, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 23 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 24 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 25 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, Through 2022 ($ Millions)
  • Table 26 Global Sales of Antibody Drugs, by Disease, Through 2022 ($ Millions)
  • Table 27 Market Shares for Antibody Drugs, by Disease, 2016 (%)
  • Table 28 Types of Autoimmune Diseases
  • Table 29 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, Through 2022 ($ Millions)
  • Table 30 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, Through 2022 ($ Millions)
  • Table 31 Types of Cancer by the Tissue of Origin
  • Table 32 Global Market for Antibody Drugs in Solid Tumors, by Type, Through 2022 ($ Millions)
  • Table 33 Global Market for Antibody Drugs in Solid Tumors, by Region, Through 2022 ($ Millions)
  • Table 34 Types of Leukemia
  • Table 35 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, Through 2022 ($ Millions)
  • Table 36 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, Through 2022 ($ Millions)
  • Table 37 Global Market for Antibody Drugs in Other Diseases, by Type, Through 2022 ($ Millions)
  • Table 38 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions)
  • Table 39 Leading Manufacturer of Murine Monoclonal Antibodies, 2016
  • Table 40 Leading Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016
  • Table 41 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%)
  • Table 42 Leading Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016
  • Table 43 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%)
  • Table 44 Leading Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016
  • Table 45 Market Shares of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)
  • Table 46 New Approvals of Monoclonal Antibodies, 2014-January 2017
  • Table 47 Recalls, 2014-January 2017
  • Table 48 Safety Alerts, 2014-January 2017
  • Table 49 Number of Patents, by Year, 2014-January 2017
  • Table 50 Number of Patents, by Type, 2014-January 2017
  • Table 51 Number of Patents, by Company, 2014-January 2017
  • Table 52 Number of Patents, by Country, 2014-January 2017
  • Table 53 Share of Patents by Country, 2014-January 2017 (No./%)
  • Table 54 Number of Patents, by Assignee, 2014-January 2017.
  • Table 55 Monoclonal Antibodies in Phase I Clinical Trials
  • Table 56 Monoclonal Antibodies in Phase II Clinical Trials
  • Table 57 Monoclonal Antibodies in Phase III Clinical Trials
  • Table 58 Monoclonal Antibodies in Phase IV Clinical Trials
  • Table 59 Mergers and Acquisitions of Top Pharmaceutical Companies, 2014-January 2017
  • Table 60 Abbreviations Used in the Antibody Drug Industry

List of Figures

  • Summary Figure Global Market for Antibody Drugs, by Disease, 2014-2022 ($ Millions)
  • Figure 1 Global Sales of Antibody Drugs, by Type, 2014-2022 ($ Millions)
  • Figure 2 Market Shares of Antibody Drugs, by Type, 2016 (%)
  • Figure 3 Global Sales of Antibody Drugs, by Region, 2014-2022 ($ Millions)
  • Figure 4 Market Shares for Antibody Drugs, by Region, 2016 (%)
  • Figure 5 Global Market for Murine Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 6 Global Market for Chimeric Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 7 Global Market for Human Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 8 Global Market for Humanized Monoclonal Antibodies, by Region, 2014-2022 ($ Millions)
  • Figure 9 Global Market for Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 10 Market Shares for Antibody Drugs, by Manufacturing Process, 2016 (%)
  • Figure 11 Global Market for Murine Antibody Drugs, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 12 Global Market for Chimeric Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 13 Global Market for Human Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 14 Global Market for Humanized Monoclonal Antibodies, by Manufacturing Process, 2014-2022 ($ Millions)
  • Figure 15 Global Sales of Antibody Drugs, by Disease, 2014-2022 ($ Millions).
  • Figure 16 Market Shares for Antibody Drugs, by Disease, 2016 (%)
  • Figure 17 Global Market for Antibody Drugs in Autoimmune Diseases, by Type, 2014-2022 ($ Millions)
  • Figure 18 Global Market for Antibody Drugs in Autoimmune Diseases, by Region, 2014-2022 ($ Millions)
  • Figure 19 Global Market for Antibody Drugs in Solid Tumors, by Type, 2014-2022 ($ Millions)
  • Figure 20 Global Market for Antibody Drugs in Solid Tumors, by Region, 2014-2022 ($ Millions)
  • Figure 21 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Type, 2014-2022 ($ Millions)
  • Figure 22 Global Market for Antibody Drugs in Lymphoma and Leukemia, by Region, 2014-2022 ($ Millions)
  • Figure 23 Global Market for Antibody Drugs in Other Diseases, by Type, 2014-2022 ($ Millions)
  • Figure 24 Global Market for Antibody Drugs in Other Diseases, by Region, Through 2022 ($ Millions)
  • Figure 25 Market Shares of Manufacturers/Suppliers of Chimeric Monoclonal Antibodies, 2016 (%)
  • Figure 26 Market Shares of Manufacturers/Suppliers of Humanized Monoclonal Antibodies, 2016 (%)
  • Figure 27 Market Share of Manufacturers/Suppliers of Human Monoclonal Antibodies, 2016 (%)
  • Figure 28 Number of Patents, by Year, 2014-January 2017
  • Figure 29 Number of Patents, by Type, 2014-January 2017
  • Figure 30 Share of Patents, by Country, 2014-January 2017 (%)
  • Figure 31 Number of Patents, by Assignee, 2014-January 2017
Back to Top